Real-world analysis demonstrates small airways disease affects treatment responses in severe asthma, suggesting risk stratification benefits.
In a real-world severe asthma cohort, baseline SAD, particularly when identified by oscillometry, was associated with subsequent non-response to biologic therapy, suggesting potential value for risk stratification.
No takes yet. Share an insight, caveat, or question.
Allegrini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: